Tourmaline Bio, Inc.
US ˙ NasdaqGS ˙ US89157D1054

Introduction

This page provides a comprehensive analysis of the known insider trading history of Francois Nader. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Francois Nader has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:TALS / Talaris Therapeutics Inc Director 386,932
US:MRNA / Moderna, Inc. Director 16,620
US:XLRN / Acceleron Pharma Inc Director 0
US:US00C4W1JQ50 / Alexion Pharmaceuticals, Inc. Director 0
Director 0
US:BXLT / Baxalta Incorporated Director 0
US:TRVN / Trevena, Inc. Director 8,870
US:NPSP / NPS Pharmaceuticals Inc President, CEO and Director, Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Francois Nader. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases TRML / Tourmaline Bio, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in TRML / Tourmaline Bio, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-07-21 TALS Nader Francois 36,500 3.7200 36,500 3.7200 135,780 14 5.0300 47,815 35.22
2022-07-20 TALS Nader Francois 52,000 3.6200 52,000 3.6200 188,240
2022-07-19 TALS Nader Francois 50,000 3.5200 50,000 3.5200 176,000
2022-07-19 TALS Nader Francois 50,000 3.5200 50,000 3.5200 176,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRML / Tourmaline Bio, Inc. Insider Trades
Insider Sales TRML / Tourmaline Bio, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in TRML / Tourmaline Bio, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRML / Tourmaline Bio, Inc. Insider Trades
Insider Purchases TRVN / Trevena, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in TRML / Tourmaline Bio, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRVN / Trevena, Inc. Insider Trades
Insider Sales TRVN / Trevena, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in TRML / Tourmaline Bio, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRVN / Trevena, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Francois Nader as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2022-09-13 2022-07-25 4/A TALS Talaris Therapeutics, Inc.
Common Stock
J - Other 138,500 386,932 55.75
2022-09-13 2022-07-25 4/A TALS Talaris Therapeutics, Inc.
Common Stock
J - Other -138,500 0 -100.00
2022-09-13 2022-07-21 4/A TALS Talaris Therapeutics, Inc.
Common Stock
P - Purchase 36,500 138,500 35.78 3.72 135,780 515,220
2022-09-13 2022-07-21 4/A TALS Talaris Therapeutics, Inc.
Common Stock
J - Other 248,432 248,432
2022-09-13 2022-07-21 4/A TALS Talaris Therapeutics, Inc.
Common Stock
J - Other -248,432 147,255 -62.78
2022-09-13 2022-07-20 4/A TALS Talaris Therapeutics, Inc.
Common Stock
P - Purchase 52,000 102,000 104.00 3.62 188,240 369,240
2022-09-13 2022-07-19 4/A TALS Talaris Therapeutics, Inc.
Common Stock
P - Purchase 50,000 50,000 3.52 176,000 176,000
2022-07-25 2022-07-25 4 TALS Talaris Therapeutics, Inc.
Common Stock
J - Other 138,500 386,932 55.75
2022-07-25 2022-07-25 4 TALS Talaris Therapeutics, Inc.
Common Stock
J - Other -138,500 0 -100.00
2022-07-25 2022-07-21 4 TALS Talaris Therapeutics, Inc.
Common Stock
P - Purchase 36,500 138,500 35.78 3.72 135,780 515,220
2022-07-25 2022-07-21 4 TALS Talaris Therapeutics, Inc.
Common Stock
J - Other 248,432 248,432
2022-07-25 2022-07-21 4 TALS Talaris Therapeutics, Inc.
Common Stock
J - Other -248,432 87,735 -73.90
2022-07-25 2022-07-20 4 TALS Talaris Therapeutics, Inc.
Common Stock
P - Purchase 52,000 102,000 104.00 3.62 188,240 369,240
2022-07-25 2022-07-19 4 TALS Talaris Therapeutics, Inc.
Common Stock
P - Purchase 50,000 50,000 3.52 176,000 176,000
2022-05-12 2022-05-10 4 MRNA Moderna, Inc.
Stock Option (Right to Buy)
M - Exercise X -23,100 16,620 -58.16
2022-05-12 2022-05-10 4 MRNA Moderna, Inc.
Common Stock
S - Sale -3,196 20,607 -13.43 136.10 -434,976 2,804,613
2022-05-12 2022-05-10 4 MRNA Moderna, Inc.
Common Stock
M - Exercise X 23,100 23,803 3,285.92 18.87 435,897 449,163
2022-05-02 2022-04-28 4 MRNA Moderna, Inc.
Stock Option (Right to Buy)
A - Award 5,415 5,415
2022-05-02 2022-04-28 4 MRNA Moderna, Inc.
Restricted Stock Units
M - Exercise -703 0 -100.00
2022-05-02 2022-04-28 4 MRNA Moderna, Inc.
Common Stock
M - Exercise 703 703
2021-12-16 2021-12-15 4 TALS Talaris Therapeutics, Inc.
Common Stock
G - Gift -59,520 336,167 -15.04
2021-11-22 2021-11-19 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
D - Sale to Issuer -3,222 0 -100.00
2021-11-22 2021-11-19 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
D - Sale to Issuer -8,185 0 -100.00
2021-11-22 2021-11-19 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
D - Sale to Issuer -7,500 0 -100.00
2021-11-22 2021-11-19 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
D - Sale to Issuer -20,000 0 -100.00
2021-11-22 2021-11-19 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
D - Sale to Issuer -576 0 -100.00
2021-11-22 2021-11-19 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
D - Sale to Issuer -7,500 0 -100.00
2021-11-22 2021-11-19 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
D - Sale to Issuer -10,000 0 -100.00
2021-11-22 2021-11-19 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
D - Sale to Issuer -10,000 0 -100.00
2021-11-22 2021-11-19 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
D - Sale to Issuer -7,500 0 -100.00
2021-11-22 2021-11-19 4 XLRN ACCELERON PHARMA INC
Common Stock
U - Other -6,749 0 -100.00
2021-07-23 2021-07-21 4 ALXN ALEXION PHARMACEUTICALS, INC.
Common Stock, par value $.0001 per share
D - Sale to Issuer -13,921 0 -100.00
2021-05-24 2021-05-20 4 ALXN ALEXION PHARMACEUTICALS, INC.
Common Stock, par value $.0001 per share
A - Award 673 13,921 5.08
2021-05-24 2021-05-20 4 ALXN ALEXION PHARMACEUTICALS, INC.
Common Stock, par value $.0001 per share
A - Award 1,962 13,248 17.38
2021-05-06 3 TALS Talaris Therapeutics, Inc.
Common Stock
395,687
2021-04-30 2021-04-28 4 MRNA Moderna, Inc.
Restricted Stock Units
A - Award 703 703
2021-04-30 2021-04-28 4 MRNA Moderna, Inc.
Stock Option (Right to Buy)
A - Award 4,081 4,081
2021-02-02 2021-01-29 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 3,222 3,222
2021-02-02 2021-01-29 4 XLRN ACCELERON PHARMA INC
Common Stock
A - Award 1,622 6,749 31.64
2021-01-26 2021-01-22 4 PRVL Prevail Therapeutics Inc.
Stock Option (Right to Buy)
D - Sale to Issuer -17,000 0 -100.00
2021-01-26 2021-01-22 4 PRVL Prevail Therapeutics Inc.
Stock Option (Right to Buy)
D - Sale to Issuer -32,000 0 -100.00
2021-01-26 2021-01-22 4 PRVL Prevail Therapeutics Inc.
Stock Option (Right to Buy)
D - Sale to Issuer -133,447 0 -100.00
2021-01-26 2021-01-22 4 PRVL Prevail Therapeutics Inc.
Common Stock
U - Other -23,747 0 -100.00
2020-06-19 2020-06-17 4 PRVL Prevail Therapeutics Inc.
Stock Option (Right to Buy)
A - Award 17,000 17,000
2020-05-18 2020-05-14 4 ALXN ALEXION PHARMACEUTICALS, INC.
Common Stock, par value $.0001 per share
A - Award 941 11,286 9.10
2020-05-18 2020-05-14 4 ALXN ALEXION PHARMACEUTICALS, INC.
Common Stock, par value $.0001 per share
A - Award 3,468 10,345 50.43
2020-04-30 2020-04-29 4 MRNA Moderna, Inc.
Stock Option (Right to Buy)
A - Award 18,270 18,270
2020-01-24 2020-01-22 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 8,185 8,185
2020-01-24 2020-01-22 4 XLRN ACCELERON PHARMA INC
Common Stock
A - Award 1,377 5,127 36.72
2019-12-11 2019-12-10 4 MRNA Moderna, Inc.
Stock Option (Right to Buy)
A - Award 17,889 17,889 18.87 337,565 337,565
2019-12-11 2019-12-10 4 MRNA Moderna, Inc.
Stock Option (Right to Buy)
A - Award 39,720 39,720 18.87 749,516 749,516
2019-06-25 2019-06-24 4 PRVL Prevail Therapeutics Inc.
Series B Preferred Stock
C - Conversion -23,747 0 -100.00
2019-06-25 2019-06-24 4 PRVL Prevail Therapeutics Inc.
Common Stock
C - Conversion 23,747 23,747
2019-05-17 2019-05-15 4 ALXN ALEXION PHARMACEUTICALS, INC.
Common Stock, par value $.0001 per share
A - Award 2,726 6,877 65.67
2019-01-29 2019-01-25 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 7,500 7,500
2019-01-29 2019-01-25 4 XLRN ACCELERON PHARMA INC
Common Stock
A - Award 1,250 3,750 50.00
2018-05-11 2018-05-09 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
A - Award 2,174 4,151 109.96
2018-03-05 2018-03-01 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 7,500 7,500
2018-03-05 2018-03-01 4 XLRN ACCELERON PHARMA INC
Common Stock
A - Award 1,250 2,500 100.00
2017-11-30 2017-11-29 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
A - Award 1,977 1,977
2017-03-14 2017-03-02 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 7,500 7,500
2017-03-14 2017-03-02 4 XLRN ACCELERON PHARMA INC
Common Stock
A - Award 1,250 1,250
2016-06-07 2016-06-03 4 BXLT Baxalta Inc
Stock Option (Right to Buy)
D - Sale to Issuer -5,960 0 -100.00
2016-06-07 2016-06-03 4 BXLT Baxalta Inc
Common Stock, $0.01 par value
D - Sale to Issuer -7,657 0 -100.00
2016-05-12 2016-05-10 4 BXLT Baxalta Inc
Common Stock, $0.01 par value
A - Award 4,500 7,657 142.54
2016-03-07 2016-03-03 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 10,000 10,000
2015-07-29 2015-07-27 4 BXLT Baxalta Inc
Stock Option (Right to Buy)
A - Award 5,960 5,960
2015-07-29 2015-07-27 4 BXLT Baxalta Inc
Common Stock, par value $0.01 per share
A - Award -3,140 3,140 -50.00
2015-05-21 2015-05-20 4 TRVN TREVENA INC
Stock Option (Right to Buy)
A - Award 8,870 8,870
2015-04-08 2015-04-06 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 10,000 10,000
2015-04-08 2015-01-08 4/A XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 576 576
2015-02-24 2015-02-21 4 NPSP NPS PHARMACEUTICALS INC
Performance Units
D - Sale to Issuer -115,432 0 -100.00
2015-02-24 2015-02-21 4 NPSP NPS PHARMACEUTICALS INC
Performance Units
D - Sale to Issuer -27,926 0 -100.00
2015-02-24 2015-02-21 4 NPSP NPS PHARMACEUTICALS INC
Restricted Stock Units
D - Sale to Issuer -24,302 0 -100.00
2015-02-24 2015-02-21 4 NPSP NPS PHARMACEUTICALS INC
Restricted Stock Units
D - Sale to Issuer -19,598 0 -100.00
2015-02-24 2015-02-21 4 NPSP NPS PHARMACEUTICALS INC
Restricted Stock Units
D - Sale to Issuer -80,912 0 -100.00
2015-02-24 2015-02-21 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
D - Sale to Issuer -109,602 0 -100.00
2015-02-24 2015-02-21 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
D - Sale to Issuer -82,826 0 -100.00
2015-02-24 2015-02-21 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
D - Sale to Issuer -67,636 0 -100.00
2015-02-24 2015-02-21 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
D - Sale to Issuer -154,284 0 -100.00
2015-02-24 2015-02-21 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
D - Sale to Issuer -133,125 0 -100.00
2015-02-24 2015-02-21 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
D - Sale to Issuer -104,438 0 -100.00
2015-02-24 2015-02-21 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
D - Sale to Issuer -196,018 0 -100.00
2015-02-24 2015-02-21 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
D - Sale to Issuer -106,643 0 -100.00
2015-02-24 2015-02-21 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
U - Other -276,955 0 -100.00 46.00 -12,739,930
2015-02-20 2015-02-13 4 NPSP NPS PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise -24,301 24,302 -50.00
2015-02-20 2015-02-13 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
F - Taxes -12,600 276,955 -4.35 45.88 -578,088 12,706,695
2015-02-20 2015-02-13 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 24,301 289,555 9.16
2015-02-20 2015-02-12 4 NPSP NPS PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise -9,798 19,598 -33.33
2015-02-20 2015-02-12 4 NPSP NPS PHARMACEUTICALS INC
Restricted Stock Units
A - Award 80,912 80,912
2015-02-20 2015-02-12 4 NPSP NPS PHARMACEUTICALS INC
Employee Stock Options (right to buy)
M - Exercise -653 106,643 -0.61
2015-02-20 2015-02-12 4 NPSP NPS PHARMACEUTICALS INC
Employee Stock Options (right to buy)
M - Exercise -3,262 104,438 -3.03
2015-02-20 2015-02-12 4 NPSP NPS PHARMACEUTICALS INC
Employee Stock Options (right to buy)
M - Exercise -24,466 191,534 -11.33
2015-02-20 2015-02-12 4 NPSP NPS PHARMACEUTICALS INC
Employee Stock Options (right to buy)
M - Exercise -5,625 67,636 -7.68
2015-02-20 2015-02-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
F - Taxes -4,943 265,254 -1.83 45.85 -226,637 12,161,896
2015-02-20 2015-02-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 9,798 270,197 3.76
2015-02-20 2015-02-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 653 260,399 0.25 38.27 24,990 9,965,470
2015-02-20 2015-02-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 3,262 259,746 1.27 8.21 26,781 2,132,515
2015-02-20 2015-02-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 24,466 256,484 10.54 3.34 81,716 856,657
2015-02-20 2015-02-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 5,625 232,018 2.48 3.25 18,281 754,058
2015-02-20 2015-02-07 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
F - Taxes -7,263 226,393 -3.11 45.85 -333,009 10,380,119
2015-02-20 2015-02-07 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
J - Other 20,301 233,656 9.52
2015-01-09 2015-01-08 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 576 576
2014-12-12 2014-12-11 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 20,000 20,000
2014-05-15 2014-05-14 4 TRVN TREVENA INC
Stock Option (Right to Buy)
A - Award 8,870 8,870
2014-04-18 2014-02-12 4 NPSP NPS PHARMACEUTICALS INC
Performance Units
A - Award 40,500 40,500
2014-02-14 2014-02-13 4 NPSP NPS PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise -24,301 48,603 -33.33
2014-02-14 2014-02-13 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
F - Taxes -11,767 233,656 -4.79 38.30 -450,676 8,949,025
2014-02-14 2014-02-13 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 24,301 245,423 10.99
2014-02-14 2014-02-12 4 NPSP NPS PHARMACEUTICALS INC
Restricted Stock Units
A - Award 29,396 29,396
2014-02-14 2014-02-12 4 NPSP NPS PHARMACEUTICALS INC
Employee Stock Options (right to buy)
A - Award 107,296 107,296
2014-02-11 2014-02-07 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
F - Taxes -7,258 221,122 -3.18 35.13 -254,974 7,768,016
2014-02-11 2014-02-07 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
J - Other 20,300 228,380 9.76
2014-01-31 2014-01-30 4 TRVN TREVENA INC
Stock Option (Right to Buy)
A - Award 17,741 17,741
2014-01-30 3 TRVN TREVENA INC
Common Stock
0
2014-01-09 2014-01-07 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
A - Award 20,250 216,000 10.34
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -16,739 73,261 -18.60
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -10,398 109,602 -8.66
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -5,850 0 -100.00
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -4,500 0 -100.00
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -3,150 0 -100.00
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -5,746 0 -100.00
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -4,875 0 -100.00
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -3,750 0 -100.00
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -2,625 0 -100.00
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -9,030 0 -100.00
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -2,771 0 -100.00
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -2,308 0 -100.00
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -1,775 0 -100.00
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -1,243 0 -100.00
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise -64,356 0 -100.00
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 16,739 226,936 7.96 3.25 54,402 737,542
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 10,398 210,197 5.20 5.71 59,373 1,200,225
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 5,850 199,799 3.02 6.16 36,036 1,230,762
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 4,500 193,949 2.38 5.85 26,325 1,134,602
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 3,150 189,449 1.69 5.05 15,908 956,717
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 5,746 186,299 3.18 3.60 20,686 670,676
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 4,875 180,553 2.77 3.93 19,159 709,573
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 3,750 175,678 2.18 4.10 15,375 720,280
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 2,625 171,928 1.55 4.42 11,602 759,922
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 9,030 169,303 5.63 4.13 37,294 699,221
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 2,771 160,273 1.76 4.31 11,943 690,777
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 2,308 157,502 1.49 4.37 10,086 688,284
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 1,775 155,194 1.16 4.50 7,988 698,373
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 1,243 153,419 0.82 4.07 5,059 624,415
2013-12-16 2013-12-12 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 64,356 152,176 73.28 5.73 368,760 871,968
2013-09-30 2013-09-27 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
M - Exercise X -9,800 82,826 -10.58
2013-09-30 2013-09-27 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
M - Exercise X -16,650 5,850 -74.00
2013-09-30 2013-09-27 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
M - Exercise X -17,008 4,500 -79.08
2013-09-30 2013-09-27 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
S - Sale X -43,458 87,820 -33.10 32.36 -1,406,118 2,841,486
2013-09-30 2013-09-27 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 9,800 131,278 8.07 5.71 55,958 749,597
2013-09-30 2013-09-27 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 16,650 121,478 15.88 6.16 102,564 748,304
2013-09-30 2013-09-27 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 17,008 104,828 19.37 5.85 99,497 613,244
2013-09-30 2013-09-26 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
M - Exercise X -992 21,508 -4.41
2013-09-30 2013-09-26 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
M - Exercise X -19,350 3,150 -86.00
2013-09-30 2013-09-26 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
S - Sale X -6,497 87,820 -6.89 33.60 -218,299 2,950,752
2013-09-30 2013-09-26 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
S - Sale X -143,503 94,317 -60.34 33.07 -4,745,644 3,119,063
2013-09-30 2013-09-26 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 992 237,820 0.42 5.85 5,803 1,391,247
2013-09-30 2013-09-26 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 19,350 236,828 8.90 5.05 97,718 1,195,981
2013-04-10 2013-04-10 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -54,000 54,000 -50.00
2013-04-10 2013-04-10 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -16,754 5,746 -74.46
2013-04-10 2013-04-10 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -58,231 0 -100.00
2013-04-10 2013-04-10 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
S - Sale X -148,367 217,478 -40.55 11.68 -1,732,526 2,539,556
2013-04-10 2013-04-10 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 54,000 365,845 17.32 3.34 180,360 1,221,922
2013-04-10 2013-04-10 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 16,754 311,845 5.68 3.60 60,314 1,122,642
2013-04-10 2013-04-10 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 58,231 295,091 24.58 3.85 224,189 1,136,100
2013-04-10 2013-04-09 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -41,769 58,231 -41.77
2013-04-10 2013-04-09 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -13,875 4,875 -74.00
2013-04-10 2013-04-09 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -15,000 3,750 -80.00
2013-04-10 2013-04-09 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -79,356 0 -100.00
2013-04-10 2013-04-09 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
S - Sale X -150,000 236,860 -38.77 11.27 -1,689,840 2,668,370
2013-04-10 2013-04-09 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 41,769 386,860 12.10 3.85 160,811 1,489,411
2013-04-10 2013-04-09 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 13,875 345,091 4.19 3.93 54,529 1,356,208
2013-04-10 2013-04-09 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 15,000 331,216 4.74 4.10 61,500 1,357,986
2013-04-10 2013-04-09 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 79,356 316,216 33.50 4.29 340,437 1,356,567
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -15,358 79,356 -16.22
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -16,125 2,625 -86.00
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -55,470 9,030 -86.00
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -6,104 2,771 -68.78
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -6,567 2,308 -73.99
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -7,100 1,775 -80.00
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -7,632 1,243 -85.99
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
M - Exercise X -35,644 64,356 -35.64
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
S - Sale X -150,000 236,860 -38.77 11.01 -1,650,795 2,606,715
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 15,358 386,860 4.13 4.29 65,886 1,659,629
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 16,125 371,502 4.54 4.42 71,272 1,642,039
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 55,470 355,377 18.50 4.13 229,091 1,467,707
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 6,104 299,907 2.08 4.31 26,308 1,292,599
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 6,567 293,803 2.29 4.37 28,698 1,283,919
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 7,100 287,236 2.53 4.50 31,950 1,292,562
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 7,632 280,136 2.80 4.07 31,062 1,140,154
2013-04-10 2013-04-08 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise X 35,644 272,504 15.05 5.73 204,240 1,561,448
2013-02-21 2013-02-19 4 NPSP NPS PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise -50,000 50,000 -50.00
2013-02-21 2013-02-19 4 NPSP NPS PHARMACEUTICALS INC
Common stock
F - Taxes -21,624 236,126 -8.39 8.01 -173,208 1,891,369
2013-02-21 2013-02-19 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
M - Exercise 50,000 257,750 24.07
2013-02-15 2013-02-13 4 NPSP NPS PHARMACEUTICALS INC
Restricted Stock Units
A - Award 72,904 72,904
2013-02-15 2013-02-13 4 NPSP NPS PHARMACEUTICALS INC
Employee Stock Options (right to buy)
A - Award 196,018 196,018
2013-02-11 2013-02-07 4 NPSP NPS PHARMACEUTICALS INC
Common stock
F - Taxes -7,193 207,750 -3.35 8.61 -61,932 1,788,728
2013-02-11 2013-02-07 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
J - Other 20,299 214,943 10.43
2012-12-26 2012-12-21 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
F - Taxes -11,068 154,043 -6.70 9.10 -100,719 1,401,791
2012-12-21 2012-12-21 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
A - Award 108,000 108,000
2012-02-09 2012-02-07 4 NPSP NPS PHARMACEUTICALS INC
Stock Option
A - Award 107,700 107,700
2012-02-09 2012-02-07 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
A - Award 60,900 60,900
2012-02-09 2012-02-07 4 NPSP NPS PHARMACEUTICALS INC
Common Stock
A - Award 60,900 60,900
2012-02-01 2012-01-20 4 NPSP NPS PHARMACEUTICALS INC
Options (right to buy)
A - Award 46,313 46,313
2012-02-01 2012-01-30 4 NPSP NPS PHARMACEUTICALS INC
Stock Options
A - Award 54,000 54,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)